Immunoforge Co. Ltd.
ImmunoForge is a biopharmaceutical company specializing in novel drug development based on long-acting platform technology. They focus on creating first-in-class drugs for rare and intractable diseases, utilizing their proprietary elastin-like polypeptide (ELP) platform to extend the half-life of proteins and peptides, enabling more convenient dosing regimens and improved patient compliance. Their mission is to develop effective treatments for patients suffering from various serious conditions, including muscular dystrophies, autoimmune diseases, and cancers, with a vision to become a global leader in innovative biopharmaceuticals.
Industries
Nr. of Employees
small (1-50)
Immunoforge Co. Ltd.
08591 Seoul, Gasan Digital 1-Ro, Geumcheon-gu, Seoul, Republic of Korea
Patents
Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
US-10993993-B2
View DetailsUse of modified vasoactive intestinal peptides in the treatment of hypertension
US-10940182-B2
View DetailsPharmaceutical composition for treating sarcopenia including glucagon-like peptide-1 receptor agonist
US-10751392-B2
View Details
Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
US-10993993-B2
View DetailsUse of modified vasoactive intestinal peptides in the treatment of hypertension
US-10940182-B2
View DetailsPharmaceutical composition for treating sarcopenia including glucagon-like peptide-1 receptor agonist
US-10751392-B2
View DetailsProducts
ELP-based half-life extension platform
Recombinant elastin-like polypeptide (ELP) biopolymer platform for extending half-life and enabling sustained-release of peptide and protein therapeutics via fusion constructs.
Froniglutide (ELP-fused GLP-1R agonist) — pipeline candidate
ELP-fused GLP-1 receptor agonist developed for muscle atrophy indications (e.g., polymyositis/dermatomyositis, DMD/BMD, sarcopenia) to enable once-weekly dosing.
Pemziviptadil (ELP-fused VPAC2 agonist) — pipeline candidate
ELP-engineered peptide targeting VPAC2 intended for cardiomyopathy in Duchenne muscular dystrophy and other cardiac indications; designed for once-weekly administration.
PF1805 (CNP-ELP) — pipeline candidate
C-type natriuretic peptide fused to ELP for once-weekly subcutaneous treatment of achondroplasia; preclinical data show effect on linear growth in mice.
PF1806 (GLP-2-ELP) — pipeline candidate
GLP-2 fused to ELP for once-weekly dosing to treat short bowel syndrome and related intestinal disorders; preclinical models showed improved intestinal effects versus daily comparator.
PF1807 (monthly GLP-1R ELP candidate) — pipeline candidate
ELP-fused GLP-1 receptor agonist designed for once-monthly dosing to address sarcopenia and related indications.
ELP-based half-life extension platform
Recombinant elastin-like polypeptide (ELP) biopolymer platform for extending half-life and enabling sustained-release of peptide and protein therapeutics via fusion constructs.
Froniglutide (ELP-fused GLP-1R agonist) — pipeline candidate
ELP-fused GLP-1 receptor agonist developed for muscle atrophy indications (e.g., polymyositis/dermatomyositis, DMD/BMD, sarcopenia) to enable once-weekly dosing.
Pemziviptadil (ELP-fused VPAC2 agonist) — pipeline candidate
ELP-engineered peptide targeting VPAC2 intended for cardiomyopathy in Duchenne muscular dystrophy and other cardiac indications; designed for once-weekly administration.
PF1805 (CNP-ELP) — pipeline candidate
C-type natriuretic peptide fused to ELP for once-weekly subcutaneous treatment of achondroplasia; preclinical data show effect on linear growth in mice.
PF1806 (GLP-2-ELP) — pipeline candidate
GLP-2 fused to ELP for once-weekly dosing to treat short bowel syndrome and related intestinal disorders; preclinical models showed improved intestinal effects versus daily comparator.
PF1807 (monthly GLP-1R ELP candidate) — pipeline candidate
ELP-fused GLP-1 receptor agonist designed for once-monthly dosing to address sarcopenia and related indications.
Services
Non-clinical efficacy, ADME, toxicology and animal model studies to support regulatory filings.
Clinical trial planning and execution, IND preparation and regulatory interactions for Phase I/II studies.
Licensing of half-life extension platform technology and transfer of platform assets to partners.
Oversight of contract manufacturing, process development for formulation and production of clinical trial material.
Global business development, alliance management and out-licensing of programs.
Non-clinical efficacy, ADME, toxicology and animal model studies to support regulatory filings.
Clinical trial planning and execution, IND preparation and regulatory interactions for Phase I/II studies.
Licensing of half-life extension platform technology and transfer of platform assets to partners.
Oversight of contract manufacturing, process development for formulation and production of clinical trial material.
Global business development, alliance management and out-licensing of programs.
Expertise Areas
- Half-life extension platform development
- Fusion protein biologics
- Preclinical development and IND preparation
- Clinical trial management (Phase I/II)
Key Technologies
- Elastin-like polypeptide (ELP) fusion proteins
- Recombinant E. coli expression
- Temperature-responsive depot-forming biopolymers
- Fc-fusion and dual-ligand fusion constructs